DelveInsight’s ‘Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the CLBP, historical and forecasted epidemiology as well as the CLBP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The CLBP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CLBP market size from 2019 to 2032. The Report also covers current CLBP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019–2032
CLBP Overview
Chronic low back pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is widespread and likely to affect everyone at one point. The exact cause of lower back pain is not found yet. Lower back pain that is long-term (for more than 3 months) is called CLBP. This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe. CLBP is the second leading cause of disability worldwide, being a major welfare and economic problem. The prevalence of CLBP in adults has increased significantly in the last decade and is continuously increasing vividly in the aging population. This condition affects men and women in all ethnic groups equally. This disease also leads to stress, depression, and anxiety. CLBP has adverse physical and psychological repercussions. It creates a significant economic burden due to loss of function, loss of work productivity, treatment costs, and disability payments.
CLBP originates from different conditions and may start from diseases, injuries, or stress to many different anatomic structures, including bones, muscles, ligaments, joints, nerves, or the spinal cord. The affected structure sends a signal through nerve endings, up to the spinal cord and into the brain, where it registers as pain.
Several theories have been given to explain or find out the exact underlying cause of CLBP, but it is believed that the nerve pathways that carry the pain signals from the nerve endings through the spinal cord and to the brain may become sensitized. Sensitization of these pathways may increase the frequency or intensity of the signals with which pain is perceived. Sometimes when the condition has been treated, the sensitized pathway continues to send signals to the brain, which sometimes, with great intensity, causes immense pain and feels just as real as the pain caused by the original injury or disease.
Continued in the report…..
CLBP Diagnosis
CLBP is usually investigated by physician evaluation or by imaging studies. The primary goal of diagnosis is to characterize the pain as mechanical, primarily when history is obtained from a patient with CLBP and sciatica. Mechanical or activity-related spinal pain is most often aggravated by static loading of the spine (prolonged sitting or standing), long-lever activities (vacuuming or working with the arms elevated and away from the body), and levered postures (forward bending of the lumbar spine). Pain is reduced when multidirectional forces balance the spine (walking or constantly changing positions) and when the spine is unloaded. Patients with mechanical LBP often prefer to lie still in bed. In contrast, those with a vascular or visceral cause are often found writhing in pain, unable to find a comfortable position.
Continued in the report…..
CLBP Treatment
CLBP is the most prevalent chronic pain condition and the second most common cause of disability in the US, after arthritis or rheumatism. CLBP may be nociceptive or neuropathic or include both components. The presence of a neuropathic component is related to the more intense pain of longer duration and a higher prevalence of comorbidities. The actual mechanism and cause of CLBP are still unknown, and due to this situation, there are no universally accepted treatment guidelines, and the management of the treatment is limited. If the source of the pain is not known or cannot be treated, the best option remains is to reduce the flare-ups and to make the pain manageable with nonsurgical treatments. There are nonsurgical treatments (physical therapy, diet, meditation, and lifestyle modifications), injection-based treatments, and pharmacologic treatments.
Continued in the report…..
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent population of CLBP, total diagnosed prevalent population of CLBP, gender-specific diagnosed prevalence of CLBP, and age-specific diagnosed prevalence of CLBP scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Key Findings
The epidemiology segment also provides the CLBP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
CLBP Emerging Drugs
Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
Brixadi (CAM2038/buprenorphine injection depot) is a novel, ready-to-use, long-acting, investigational buprenorphine weekly and monthly subcutaneous depot injection for flexible and individualized treatment of both moderate-to-severe opioid use disorder and moderate-to-severe chronic pain. The drug is a partial agonist at the mu-opioid receptor and exhibits antagonistic effects at the kappa opioid receptor.
Semdexa (SP-102): Scilex Holding
Semdexa (SP-102, dexamethasone sodium phosphate) is a nonopioid corticosteroid formulated as a viscous gel injection that is under development to treat lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents, or particulates. Because of these properties, the drug is expected to result in a better safety profile than commonly used off-label injected corticosteroids. SP-102 has an ingredient that is a widely used corticosteroid solution. Corticosteroids have been given epidurally (directly into the spine) for the pain caused by sciatica since about 1970; however, there is no US FDA–approved injectable corticosteroid for sciatica. SP-102 is a treatment intended to produce an anti‑inflammatory effect from the widely used corticosteroid solution, and it is intended to last longer than other steroid injections possibly used by your doctor to treat sciatica.
Products detail in the report…
List to be continued in the report…
CLBP is a complex process and comparable to how each patient has a very individualized disease process the treatment regimen is similarly individualized. There are several different medication classes, each with an exclusive mechanism of action that can help the practitioner in targeting a specific aspect of a patient's pain. Moreover, patient‐specific factors are taken into account when developing a regimen to ensure adherence and improve outcomes.
Prior to initiating any pharmacologic treatment regimen for a patient, current consensus recommendations include discussing realistic expectations with the patient. This includes the expectation of a patient in terms of pain relief as well as functional goals that the patient should work toward. Additionally, clinicians encourage self‐care and education with evidence‐based materials.
Continued in the report…..
Key Findings
The United States CLBP Market Outlook
This section provides the total CLBP market size and; market size by therapies in the United States.
EU-5 CLBP Market Outlook
The total CLBP market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan CLBP Market Outlook
The total CLBP market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the CLBP market or expected to get launched in the market during the study period 2019–2032. The analysis covers the CLBP market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for CLBP emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive and market Intelligence analysis of the CLBP market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
1. Key Insights
2. Report Introduction
3. Chronic Lower Back Pain Market Overview at a Glance
3.1. Market Share (%) of Chronic Lower Back Pain by Therapies in 2019
3.2. Market Share (%) of Chronic Lower Back Pain by Therapies in 2032
4. Executive Summary of Chronic lower back pain (CLBP)
5. Key Events
6. Chronic Lower Back Pain (CLBP): Disease Background and Overview
6.1. Introduction
6.2. Signs and Symptoms
6.3. Causes and Risk Factors
6.4. Genetics of Chronic Lower Back Pain
6.5. Pathophysiology
6.6. Types of pain
6.7. Diagnosis
6.7.1. Test for CLAB diagnosis
6.7.2. Imaging guidelines
6.8. Treatment and Management
6.8.1. Treatment Approaches
6.8.2. Treatment Algorithm
6.8.3. Proposed Guidelines for Chronic Lower Back Pain
6.8.3.1. NICE Guidelines
6.8.3.2. Center for Disease Control and Prevention (CDC) Guidelines
6.8.3.3. American College of Physicians (ACP) Guidelines
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Methodology
7.3. Total Prevalent Cases of Chronic Lower Back Pain in the 7MM
7.4. Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM
7.5. The United States
7.5.1. Assumptions and Rationale
7.5.2. Total Prevalent Population of Chronic Lower Back Pain in the United States
7.5.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States
7.5.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
7.5.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
7.6. EU5
7.6.1. Assumptions and Rationale
7.6.2. Total Prevalent Population of Chronic Lower Back Pain in EU-5
7.6.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5
7.6.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5
7.6.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5
7.7. Japan
7.7.1. Assumptions and Rationale
7.7.2. Total Prevalent Population of Chronic Lower Back Pain in Japan
7.7.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan
7.7.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
7.7.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
8. Patient Journey
9. CLBP Marketed Therapies
9.1. Key Cross Competition
9.2. Cymbalta (Duloxetine): Eli Lilly and Company
9.2.1. Product Description
9.2.2. Regulatory Milestones
9.2.3. Other Developmental Activities
9.2.4. Clinical development
9.2.5. Clinical Trials Information
9.2.6. Safety and Efficacy
9.2.7. Product Profile
9.3. Xtampza: Collegium Pharmaceutical
9.3.1. Product Description
9.3.2. Regulatory Milestones
9.3.3. Other Developmental Activities
9.3.4. Clinical Development
9.3.5. Clinical trial information
9.3.6. Safety and Efficacy
9.3.7. Product Profile
9.4. Hysingla ER: Purdue Pharma LP
9.4.1. Product Description
9.4.2. Regulatory Milestones
9.4.3. Other Developmental Activities
9.4.4. Clinical Development
9.4.5. Clinical trial information
9.4.6. Safety and Efficacy
9.4.7. Product Profile
9.5. Butrans (buprenorphine): Purdue Pharma
9.5.1. Product Description
9.5.2. Regulatory Milestones
9.5.3. Clinical Development
9.5.4. Clinical Trials Information
9.5.5. Safety and Efficacy
9.5.6. Product Profile
9.6. Belbuca: BioDelivery Sciences International
9.6.1. Product Description
9.6.2. Regulatory Milestones
9.6.3. Other Developmental activities
9.6.4. Clinical Development
9.6.5. Clinical Trials Information
9.6.6. Safety and Efficacy
9.6.7. Product Profile
10. Emerging Therapies
10.1. Key Cross Competition
10.2. Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
10.2.1. Drug Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.2.7. Analysts’ Views
10.3. Semdexa (SP-102): Scilex Holding
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.3.7. Analysts’ Views
10.4. Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
10.4.1. Drug Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.4.7. Analysts’ Views
10.5. AMG0103: AnGes MG, Inc.
10.5.1. Drug Description
10.5.2. Clinical Development
10.5.3. Clinical Trials Information
10.5.4. Safety and Efficacy
10.5.5. Product Profile
10.5.6. Analysts’ Views
10.6. KLS-2031: Kolon Life Science
10.6.1. Drug Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Clinical Trials Information
10.6.5. Product Profile
10.6.6. Analysts’ Views
10.7. ETX-810: Eliem Therapeutics
10.7.1. Drug Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Clinical Trials Information
10.7.5. Product Profile
10.7.6. Analysts’ Views
10.8. ALLOD-2: Allodynic Therapeutics
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.4. Clinical Trials Information
10.8.5. Product Profile
10.9. FB3001: Frontier Biotechnologies
10.9.1. Drug Description
10.9.2. Other Developmental Activities
10.9.3. Clinical Development
10.9.4. Clinical Trial Information
10.9.5. Safety and efficacy
10.9.6. Product profile
10.10. IDCT (rebonuputemcel): DiscGenics Inc.
10.10.1. Drug Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Developmental Activities
10.10.4. Clinical trial information
10.10.5. Safety and efficacy
10.10.6. Product Profile
10.10.7. Analysts’ Views
10.11. SX600: SpineThera
10.11.1. Product Description
10.11.2. Other Developmental Activities
10.11.3. Clinical Development
10.11.4. Clinical Trials Information
10.11.5. Product Profile
10.12. STA363: Stayble Therapeutics
10.12.1. Product Description
10.12.2. Other Developmental Activities
10.12.3. Clinical Development
10.12.4. Clinical Trials Information
10.12.5. Product Profile
10.13. Clonidine Micropellets (STX-015): Sollis Therapeutics/Medtronic Spinal and Biologics
10.13.1. Product Description
10.13.2. Other Development Activities
10.13.3. Clinical development
10.13.4. Clinical Trials Information
10.13.5. Safety and Efficacy
10.13.6. Product Profile
10.14. Tanezumab: Eli Lilly/Pfizer
10.14.1. Product Description
10.14.2. Other Developmental Activities
10.14.3. Clinical Development
10.14.4. Clinical Trials Information
10.14.5. Safety and Efficacy
10.14.6. Product Profile
10.14.7. Analysts’ Views
10.15. LY3556050: Eli Lilly and Company
10.15.1. Drug Description
10.15.2. Clinical Development
10.15.3. Clinical Trials Information
10.15.4. Product Profile
10.16. PP353: Persica Pharmaceuticals
10.16.1. Drug Description
10.16.2. Other Developmental Activities
10.16.3. Clinical Development
10.16.4. Clinical Trials Information
10.16.5. Product Profile
10.17. BRTX-100: BioRestorative Therapies
10.17.1. Drug Description
10.17.2. Other Developmental Activities
10.17.3. Clinical Development
10.17.4. Clinical Trials Information
10.17.5. Product Profile
10.17.6. Analysts’ Views
10.18. VER-01: Vertanical GmbH
10.18.1. Drug Description
10.18.2. Clinical Development
10.18.3. Clinical Trials Information
10.18.4. Product Profile
10.19. BM-MSC/ReSpine: Montpellier University Hospital
10.19.1. Product Description
10.19.2. Clinical development
10.19.3. Clinical Trials Information
10.19.4. Product Profile
11. Failed therapies
11.1. Fasinumab (REGN475): Regeneron Pharmaceuticals/Teva Pharmaceuticals
11.1.1. Product Description
11.1.2. Other Developmental Activities
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Product Profile
12. Chronic Lower Back Pain: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Methodology
12.3. CLBP Market Outlook
12.3.1. United States
12.3.2. EU-5 countries
12.3.3. Japan CLBP Market
12.4. Attribute Analysis
12.5. Potential of Emerging Therapies of Chronic Low Back Pain
12.6. Key Market Forecast Assumptions
12.7. Market size of Chronic Lower Back Pain in the 7MM
12.8. Market size of Chronic Lower Back Pain by Therapies in the 7MM
12.9. Market size of Chronic Lower Back Pain in the United States
12.9.1. Total Market size of Chronic Lower Back Pain in the United States
12.9.2. Market Size by Therapies in the US
12.10. Market size of Chronic Lower Back Pain in EU-5
12.10.1. Total Market size of Chronic Lower Back Pain in EU5
12.10.2. Market Size of Chronic Lower Back Pain in EU5 by Therapies
12.11. Market size of Chronic Lower Back Pain in Japan
12.11.1. Total Market size of Chronic Lower Back Pain
12.11.2. Market Size by Therapies in Japan
13. KOL Views
14. CLBP Market Drivers
15. CLBP Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. CLBP Market Access and Reimbursement
19. Appendix
19.1. Report Methodology
19.2. Bibliography
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
List of Table
Table 1: Summary of CLBP Market and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: Risk Factors for Occurrence and Chronicity of Low Back Pain
Table 4: Cause of Muscle Connective Tissue Fibrosis
Table 5: Clinical Evaluation
Table 6: Graded Chronic Pain Scale (GCPS)
Table 7: Summary of the Efficacy of Physical Treatments for Chronic LBP
Table 8: The American College of Physicians Guideline Grading System
Table 9: Clinical Practice Guideline From the American College of Physicians
Table 10: Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Table 11: Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Table 12: Total Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Table 13: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Table 14: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019–2032)
Table 15: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019–2032)
Table 16: Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)
Table 17: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)
Table 18: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)
Table 19: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU5 (2019–2032)
Table 20: Total Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Table 21: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Table 22: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Table 23: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Table 24: Key Cross of Approved Drugs
Table 25: Cymbalta, Clinical Trial Description, 2021
Table 26: Xtampza ER, Clinical Trial Description, 2021
Table 27: Hysingla ER, Clinical Trial Description, 2021
Table 28: Butrans, Clinical Trial Description, 2021
Table 29: Belbuca, Clinical Trial Description, 2021
Table 30: Comparison of emerging drugs under development
Table 31: Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Clinical Trial Description, 2021
Table 32: Semdexa (SP-102), Clinical Trial Description, 2021
Table 33: Rexlemestrocel-L, Clinical Trial Description, 2021
Table 34: AMG0103, Clinical Trial Description, 2021
Table 35: KLS-2031, Clinical Trial Description, 2021
Table 36: ETX-810, Clinical Trial Description, 2021
Table 37: ALLOD-2, Clinical Trial Description, 2021
Table 38: FB3001, Clinical Trial Description, 2021
Table 39: IDCT, Clinical Trial Description, 2021
Table 40: SX600, Clinical Trial Description, 2021
Table 41: STA363, Clinical Trial Description, 2021
Table 42: Clonidine Micropellets, Clinical Trial Description, 2021
Table 43: Tanezumab, Clinical Trial Description 2021
Table 44: LY3556050 Clinical Trial Description, 2021
Table 45: PP353 Clinical Trial Description, 2021
Table 46: BRTX-100, Clinical Trial Description, 2021
Table 47: VER-01, Clinical Trial Description, 2021
Table 48: BM-MSC, Clinical Trial Description, 2021
Table 49: Fasinumab, Clinical Trial Description, 2021
Table 50: Key Market Forecast Assumptions for Brixadi
Table 51: Key Market Forecast Assumptions for Rexlemestrocel-L
Table 52: Key Market Forecast Assumptions for SEMDEXA/SP-102
Table 53: Key Market Forecast Assumptions for Clonidine Micropellets (STX-015)
Table 54: Key Market Forecast Assumptions for Tanezumab
Table 55: Seven Major Market Size of Chronic Lower Back Pain in USD Million (2019–2032)
Table 56: Market Size of Chronic Low Back Pain by therapies in the 7MM, in USD Million (2019–2032)
Table 57: United States Market Size of Chronic Lower Back Pain in USD Million (2019–2032)
Table 58: Market Size of Chronic Low Back Pain by therapies in the US in USD Million (2019–2032)
Table 59: EU-5 Market Size of Chronic Lower Back Pain in USD Million (2019–2032)
Table 60: Market Size of Chronic Low Back Pain by therapies in EU-5 in USD Million (2019–2032)
Table 61: Market Size of Chronic Lower Back Pain in Japan, in USD Million (2019–2032)
Table 62: Market Size of Chronic Low Back Pain by therapies in Japan in USD Million (2019–2032)
List of Figures
Figure 1: Types of Lower Back Pain
Figure 2: Definitions of Chronic Lower Back Pain
Figure 3: Signs and Symptoms of CLBP
Figure 4: Pathophysiological Model for Chronic Low Back Pain Linking Somatic and Behavioral Components
Figure 5: Relationship Describing Therapeutic Inventions and Pathogenic Mechanism
Figure 6: Types of Pain Involved in CLBP mechanism
Figure 7: The Vicious Circle showing the Interaction Of Influencing Factors
Figure 8: Treatment Algorithm for Chronic Low Back Pain
Figure 9: Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Figure 10: Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)
Figure 11: Total Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Figure 12: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)
Figure 13: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019–2032)
Figure 14: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019–2032)
Figure 15: Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)
Figure 16: Total Diagnosed Prevalent Population of CLBP in EU-5 (2019–2032)
Figure 17: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)
Figure 18: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)
Figure 19: Total Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Figure 20: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)
Figure 21: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Figure 22: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)
Figure 23: Market Size of Chronic Lower Back Pain in the 7MM, USD Millions (2019–2032)
Figure 24: Market Size of Chronic Lower Back Pain by Therapies in the 7MM, USD Millions (2019–2032)
Figure 25: Market Size of Chronic Lower Back Pain in the United States, USD Millions (2019–2032)
Figure 26: Market size of CLBP by therapies in the United States, in USD Million (2019–2032)
Figure 27: Total Market Size of Chronic Lower Back Pain in EU5, USD Millions (2019–2032)
Figure 28: Market Size of Chronic Low Back Pain by therapies in EU-5, in USD Million (2019–2032)
Figure 29: Market Size of Chronic Lower Back Pain in Japan, USD Millions (2019–2032)
Figure 30: Market Size of Chronic Low Back Pain by therapies in Japan, in USD Million (2019–2032)
Figure 31: Market Drivers
Figure 32: Market Barriers
Figure 33: Unmet Needs
Figure 34: SWOT Analysis
Eli Lilly and Company
Collegium Pharmaceutical
Purdue Pharma LP
BioDelivery Sciences International
Camurus
Braeburn Inc.
Scilex Holding
Mesoblast Limited
AnGes MG, Inc.
Kolon Life Science
Eliem Therapeutics
Allodynic Therapeutics
Sollis Therapeutics
Medtronic Spinal and Biologics
Frontier Biotechnologies
DiscGenics Inc.
Pfizer
Persica Pharmaceuticals
BioRestorative Therapies
Vertanical GmbH
Stayble Therapeutics
SpineThera
